|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
62,894,000 |
Market
Cap: |
2.08(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$22.61 - $51.88 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
246,388 |
246,388 |
246,388 |
470,243 |
Total Sell Value |
$8,325,092 |
$8,325,092 |
$8,325,092 |
$16,684,033 |
Total People Sold |
6 |
6 |
6 |
9 |
Total Sell Transactions |
7 |
7 |
7 |
15 |
End Date |
2024-03-09 |
2023-12-07 |
2023-06-08 |
2022-06-08 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Keler Tibor |
Sr. VP & CSO |
|
2009-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,868 |
5,868 |
|
- |
|
Davis Thomas Andrew |
Sr. VP & CMO |
|
2009-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,868 |
5,868 |
|
- |
|
Marucci Anthony S |
President & CEO |
|
2009-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,868 |
5,868 |
|
- |
|
Catlin Avery W |
Sr. VP & CFO |
|
2009-01-02 |
4 |
A |
$6.73 |
$673 |
D/D |
100 |
100 |
|
- |
|
Schaller Charles R |
Director |
|
2008-11-13 |
4 |
B |
$6.11 |
$18,330 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
Parekh Rajesh R |
Director |
|
2008-09-10 |
4 |
S |
$11.00 |
$23,947 |
I/I |
(2,178) |
0 |
|
- |
|
Parekh Rajesh R |
Director |
|
2008-09-09 |
4 |
S |
$11.05 |
$284,823 |
I/I |
(25,770) |
2,178 |
|
- |
|
Parekh Rajesh R |
Director |
|
2008-09-08 |
4 |
S |
$11.37 |
$321,512 |
I/I |
(28,275) |
27,948 |
|
- |
|
Medarex Inc |
10% Owner |
|
2008-06-23 |
4 |
S |
$12.35 |
$4,343,384 |
D/D |
(351,691) |
4,960,848 |
|
- |
|
Lorantis Holdings Ltd |
10% Owner |
|
2008-04-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,811,147) |
0 |
|
- |
|
Lorantis Holdings Ltd |
10% Owner |
|
2008-03-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,811,147 |
|
- |
|
Parekh Rajesh R |
Director |
|
2008-03-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
56,223 |
|
- |
|
Medarex Inc |
10% Owner |
|
2008-03-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,312,539 |
|
- |
|
Freeman Paula R |
Sr.Dir.Human Resources |
|
2008-01-02 |
4 |
A |
$0.43 |
$213 |
D/D |
500 |
2,955 |
|
- |
|
Keilani Taha |
VP Medical & Reg Affairs |
|
2008-01-02 |
4 |
A |
$0.43 |
$213 |
D/D |
500 |
2,000 |
|
- |
|
Catlin Avery W |
Sr. VP & CFO |
|
2007-07-02 |
4 |
A |
$0.71 |
$353 |
D/D |
500 |
21,500 |
|
- |
|
Ryan Una S |
President & CEO |
|
2007-07-02 |
4 |
A |
$0.71 |
$353 |
D/D |
500 |
899,213 |
|
- |
|
Paluck Thomas S |
10% Owner |
|
2007-01-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,332,232 |
|
- |
|
Paluck Thomas S |
10% Owner |
|
2007-01-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,300,114 |
|
- |
|
Catlin Avery W |
Sr. VP & CFO |
|
2006-08-16 |
4 |
B |
$1.35 |
$6,750 |
D/D |
5,000 |
21,000 |
2.74 |
- |
|
Ryan Una S |
President & CEO |
|
2006-08-16 |
4 |
B |
$1.36 |
$41,057 |
D/D |
30,300 |
898,713 |
2.81 |
- |
|
Ryan Una S |
President & CEO |
|
2006-07-03 |
4 |
A |
$1.37 |
$685 |
D/D |
500 |
868,413 |
|
- |
|
Keilani Taha |
VP Medical & Reg Affairs |
|
2006-07-03 |
4 |
A |
$1.37 |
$685 |
D/D |
500 |
1,500 |
|
- |
|
Catlin Avery W |
Sr. VP & CFO |
|
2006-07-03 |
4 |
A |
$1.37 |
$685 |
D/D |
500 |
16,000 |
|
- |
|
Lipton Karen Shoos |
Director |
|
2006-05-15 |
4 |
OE |
$1.23 |
$4,920 |
D/D |
4,000 |
4,000 |
|
- |
|
254 Records found
|
|
Page 9 of 11 |
|
|